StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Morgan Stanley on Eli Lilly (LLY): retatrutide weight loss data 'encouraging,' but offset by GI adverse events
March 19, 2026 10:14 AM
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,313.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
